Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Rhea-AI Summary

Evolus, Inc. (EOLS) announces the reporting of its fourth quarter and year-end 2023 financial results along with a business update on March 7, 2024. The company will host a conference call and live webcast to discuss the results, followed by a Q&A session.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13743722. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva^®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme^®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^®, Nuceiva^®, and Evolysse™ are trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme^® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222990989/en/

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

When will Evolus, Inc. (EOLS) report its fourth quarter and year-end 2023 financial results?

Evolus, Inc. (EOLS) will report its fourth quarter and year-end 2023 financial results on Thursday, March 7, 2024, after the U.S. financial markets close.

What time will the conference call to discuss the financial results take place?

The conference call to discuss the financial results will take place at 4:30 p.m. ET on the same day, March 7, 2024.

How can one participate in the conference call?

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website.

Where can one access the archived webcast of the conference call?

The archived webcast of the conference call can be accessed on the Investor Relations page of the Evolus website at www.evolus.com.